title: Effect of protein binding on the pharmacological activity of highly bound antibiotics.
abstract: During antibiotic drug development, media are frequently spiked with either serum/plasma or protein supplements to evaluate the effect of protein binding. Usually, previously reported serum or plasma protein binding values are applied in the analysis. The aim of this study was to evaluate this approach by experimentally measuring free, unbound concentrations for antibiotics with reportedly high protein binding and their corresponding antimicrobial activities in media containing commonly used protein supplements. Free, unbound ceftriaxone and ertapenem concentrations were determined in bacterial growth medium with and without bovine/human serum albumin, as well as adult bovine serum and human plasma using in vitro microdialysis. The corresponding antimicrobial activity was determined in MIC and time-kill curve experiments using Escherichia coli ATCC 25922 and Streptococcus pneumoniae ATCC 6303 as test strains. A semimechanistic maximum effect model was simultaneously fitted to the data and respective EC(50) (concentration at half-maximum effect) values compared. Protein binding differed significantly for ceftriaxone (P < 0.05) between human plasma (76.8 +/- 11.0%) and commercially available bovine (20.2 +/- 8.3%) or human serum albumin (56.9 +/- 16.6%). Similar results were obtained for ertapenem (human plasma, 73.8 +/- 11.6%; bovine serum albumin, 12.4 +/- 4.8%; human serum albumin, 17.8 +/- 11.5%). The MICs and EC(50)s of both strains were significantly increased (P < 0.05) for ceftriaxone when comparing human and bovine serum albumin, whereas the EC(50)s were not significantly different for ertapenem. Free, unbound antibiotic concentrations differed substantially between plasma and protein supplements and correlated well with antimicrobial efficacy. Therefore, free, active concentrations should be measured in the test system instead of correcting for literature protein binding values.
authors.affiliation: Department of Pharmaceutics, University of Florida, College of Pharmacy, Gainesville, Florida 32610-0494, USA.
authors.forename: Stephan
authors.initials: S
authors.lastname: Schmidt
authors.forename: Katharina
authors.initials: K
authors.lastname: Röck
authors.forename: Martina
authors.initials: M
authors.lastname: Sahre
authors.forename: Olaf
authors.initials: O
authors.lastname: Burkhardt
authors.forename: Martin
authors.initials: M
authors.lastname: Brunner
authors.forename: Maximilian T
authors.initials: MT
authors.lastname: Lobmeyer
authors.forename: Hartmut
authors.initials: H
authors.lastname: Derendorf
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000378:metabolism* / Q000494:pharmacology*; D001798:Blood Proteins / Q000378:metabolism*; D002417:Cattle; D002443:Ceftriaxone / Q000378:metabolism / Q000494:pharmacology; D055808:Drug Discovery; D000077727:Ertapenem; D004926:Escherichia coli / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D008954:Models, Biological; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism; D012710:Serum Albumin, Bovine / Q000378:metabolism; D013296:Streptococcus pneumoniae / Q000187:drug effects; D047090:beta-Lactams / Q000378:metabolism / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D001798:Blood Proteins; D012709:Serum Albumin; D047090:beta-Lactams; D012710:Serum Albumin, Bovine; D002443:Ceftriaxone; D000077727:Ertapenem
references.citation: Science. 2004 Sep 10;305(5690):1622-5
references.pmid: 15308767
references.citation: J Antimicrob Chemother. 2006 Sep;58(3):632-6
references.pmid: 16840426
references.citation: J Antimicrob Chemother. 2004 Jul;54(1):259-62
references.pmid: 15150172
references.citation: J Antimicrob Chemother. 2007 Jun;59(6):1185-9
references.pmid: 17412725
references.citation: Clin Chem. 1985 Jan;31(1):60-4
references.pmid: 3917383
references.citation: Farmaco Sci. 1977 Apr;32(4):303-10
references.pmid: 862884
references.citation: Antimicrob Agents Chemother. 1990 Jun;34(6):1257-8
references.pmid: 2393287
references.citation: J Antimicrob Chemother. 1983 Mar;11(3):233-8
references.pmid: 6841305
references.citation: Clin Pharmacokinet. 2001;40(9):685-94
references.pmid: 11605716
references.citation: J Antimicrob Chemother. 2004 Nov;54(5):876-80
references.pmid: 15472003
references.citation: J Antimicrob Chemother. 1998 Jul;42(1):95-8
references.pmid: 9700535
references.citation: Expert Opin Drug Discov. 2007 Jun;2(6):849-60
references.pmid: 23489002
references.citation: J Antimicrob Chemother. 2002 Oct;50(4):525-32
references.pmid: 12356797
references.citation: Clin Pharmacokinet. 1989 Oct;17(4):223-35
references.pmid: 2686882
references.citation: Antimicrob Agents Chemother. 2004 Feb;48(2):369-77
references.pmid: 14742182
references.citation: J Chemother. 1998 Feb;10(1):29-34
references.pmid: 9531073
references.citation: J Antimicrob Chemother. 2007 Dec;60(6):1388-90
references.pmid: 17951265
references.citation: J Antimicrob Chemother. 2008 Mar;61(3):561-7
references.pmid: 18216178
references.citation: Chemotherapy. 1981;27 Suppl 1:42-6
references.pmid: 7249794
references.citation: Antimicrob Agents Chemother. 1991 Dec;35(12):2505-8
references.pmid: 1667253
references.citation: Pharm Res. 1990 Oct;7(10):1077-81
references.pmid: 2281040
references.citation: Clin Pharmacol Ther. 1981 May;29(5):650-7
references.pmid: 7053242
references.citation: J Vet Pharmacol Ther. 1989 Sep;12(3):253-60
references.pmid: 2810474
references.citation: Drugs. 1981;22 Suppl 1:52-9
references.pmid: 6456892
references.citation: J Pharm Biomed Anal. 2004 Sep 3;35(5):1293-9
references.pmid: 15336375
references.citation: J Infect Dis. 1981 Apr;143(4):609-16
references.pmid: 7240802
references.citation: J Antimicrob Chemother. 2005 May;55(5):601-7
references.pmid: 15772142
references.citation: J Pharm Sci. 1997 Jan;86(1):52-6
references.pmid: 9002459
references.citation: Expert Rev Anti Infect Ther. 2005 Jun;3(3):361-73
references.pmid: 15954853
references.citation: Antimicrob Agents Chemother. 2007 Jan;51(1):128-36
references.pmid: 17060524
references.citation: J Hosp Infect. 1990 Apr;15 Suppl A:23-34
references.pmid: 1971641
references.citation: J Antimicrob Chemother. 2007 Jul;60(1):156-8
references.pmid: 17483149
references.citation: Antimicrob Agents Chemother. 1989 Jan;33(1):35-40
references.pmid: 2496656
references.citation: Int J Antimicrob Agents. 2007 Mar;29(3):263-70
references.pmid: 17194570
references.citation: Xenobiotica. 1987 Oct;17(10):1139-45
references.pmid: 3424863
references.citation: Clin Pharmacokinet. 1986 Nov-Dec;11(6):450-69
references.pmid: 3542337
references.citation: Int J Pharm. 2006 Mar 27;311(1-2):108-12
references.pmid: 16431044
references.citation: Antimicrob Agents Chemother. 2004 Sep;48(9):3419-24
references.pmid: 15328106
references.citation: J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Jan 18;830(2):218-23
references.pmid: 16290251